Display options
Cite
Cabanero M, Sangha R, Sheffield BS, et al. Management of . Curr Oncol. 2017;24(2):111-119doi: 10.3747/co.24.3524.
Cabanero, M., Sangha, R., Sheffield, B. S., Sukhai, M., Pakkal, M., Kamel-Reid, S., Karsan, A., Ionescu, D., Juergens, R. A., Butts, C., & Tsao, M. S. (2017). Management of . Current oncology (Toronto, Ont.), 24(2), 111-119. https://doi.org/10.3747/co.24.3524
Cabanero, M, et al. "Management of ." Current oncology (Toronto, Ont.) vol. 24,2 (2017): 111-119. doi: https://doi.org/10.3747/co.24.3524
Cabanero M, Sangha R, Sheffield BS, Sukhai M, Pakkal M, Kamel-Reid S, Karsan A, Ionescu D, Juergens RA, Butts C, Tsao MS. Management of . Curr Oncol. 2017 Apr;24(2):111-119. doi: 10.3747/co.24.3524. Epub 2017 Apr 27. PMID: 28490925; PMCID: PMC5407862.
Copy Download .nbib Format: NLM
Share it on

Curr Oncol. 2017 Apr;24(2):111-119. doi: 10.3747/co.24.3524. Epub 2017 Apr 27.

Management of .

Current oncology (Toronto, Ont.)

M Cabanero, R Sangha, B S Sheffield, M Sukhai, M Pakkal, S Kamel-Reid, A Karsan, D Ionescu, R A Juergens, C Butts, M S Tsao

Affiliations

  1. Princess Margaret Cancer Centre, University Health Network, Toronto, ON.
  2. Cross Cancer Institute, Edmonton, AB.
  3. BC Cancer Agency, Vancouver, BC.
  4. Juravinski Cancer Centre, McMaster University, Hamilton, ON.

PMID: 28490925 PMCID: PMC5407862 DOI: 10.3747/co.24.3524

Abstract

Starting in the early 2000s, non-small-cell lung cancer (nsclc) subtypes have evolved from being histologically described to molecularly defined. Management of lung adenocarcinomas now generally requires multiple molecular tests at baseline to define the optimal treatment strategy. More recently, second biopsies performed at progression in patients treated with tyrosine kinase inhibitors (tkis) have further defined the continued use of molecularly targeted therapy. In the present article, we focus on one molecular subtype:

Keywords: EGFR; Lung adenocarcinoma; liquid biopsies; re-biopsies; resistant mutations

Conflict of interest statement

We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare the following interests: MST declares research grants from AstraZeneca, Pfizer, and Merck, and

References

  1. N Engl J Med. 2015 Apr 30;372(18):1700-9 - PubMed
  2. Clin Cancer Res. 2006 Nov 1;12(21):6494-501 - PubMed
  3. J Clin Oncol. 2011 Aug 20;29(24):3316-21 - PubMed
  4. Transl Lung Cancer Res. 2015 Feb;4(1):67-81 - PubMed
  5. Clin Cancer Res. 2014 Mar 15;20(6):1698-705 - PubMed
  6. JAMA Oncol. 2016 Aug 1;2(8):1014-22 - PubMed
  7. Radiology. 2012 Dec;265(3):939-48 - PubMed
  8. Nat Biotechnol. 2014 May;32(5):479-84 - PubMed
  9. PLoS One. 2015 Aug 28;10(8):e0136407 - PubMed
  10. J Clin Oncol. 2008 Mar 1;26(7):1182-4; author reply 1184-6 - PubMed
  11. Oncotarget. 2016 Mar 15;7(11):12404-13 - PubMed
  12. Am J Clin Pathol. 1991 Feb;95(2):117-24 - PubMed
  13. Clin Cancer Res. 2011 Mar 1;17(5):1169-80 - PubMed
  14. Clin Chem. 2015 Oct;61(10 ):1299-304 - PubMed
  15. Science. 1965 Apr 16;148(3668):374-6 - PubMed
  16. J Thorac Oncol. 2012 Dec;7(12):1807-14 - PubMed
  17. J Thorac Oncol. 2013 Mar;8(3):346-51 - PubMed
  18. Clin Cancer Res. 2016 Mar 1;22(5):1103-10 - PubMed
  19. J Thorac Oncol. 2012 Nov;7(11):1640-4 - PubMed
  20. JAMA Oncol. 2016 Mar;2(3):305-12 - PubMed
  21. Nat Biotechnol. 2016 May;34(5):547-55 - PubMed
  22. Onco Targets Ther. 2015 May 19;8:1137-42 - PubMed
  23. Clin Cancer Res. 2015 Sep 1;21(17):3818-20 - PubMed
  24. Cancer Discov. 2014 Sep;4(9):1036-45 - PubMed
  25. Sci Transl Med. 2012 May 30;4(136):136ra68 - PubMed
  26. J Thorac Oncol. 2015 Nov;10(11):1553-9 - PubMed
  27. Nat Rev Clin Oncol. 2014 Aug;11(8):473-81 - PubMed
  28. Cancer Sci. 2016 Mar;107(3):353-8 - PubMed
  29. J Clin Oncol. 2013 Mar 10;31(8):1070-80 - PubMed
  30. Clin Cancer Res. 2013 Apr 15;19(8):2240-7 - PubMed
  31. Lancet Oncol. 2015 Apr;16(4):e165-72 - PubMed
  32. Lung Cancer. 2014 Jul;85(1):19-24 - PubMed
  33. Oncogene. 2010 Apr 22;29(16):2346-56 - PubMed
  34. J Thorac Oncol. 2016 Nov;11(11):2022-2026 - PubMed
  35. Mutat Res. 1998 Jun 5;401(1-2):77-88 - PubMed
  36. Science. 2004 Jun 4;304(5676):1497-500 - PubMed
  37. Clin Cancer Res. 2014 Dec 1;20(23):5898-907 - PubMed
  38. N Engl J Med. 2015 Apr 30;372(18):1689-99 - PubMed
  39. Pathobiology. 2000;68(4-5):215-7 - PubMed
  40. N Engl J Med. 2004 May 20;350(21):2129-39 - PubMed
  41. Clin Lung Cancer. 2017 Jan;18(1):34-42.e2 - PubMed
  42. J Oncol. 2015;2015:809835 - PubMed
  43. PLoS Med. 2005 Mar;2(3):e73 - PubMed
  44. Science. 2007 May 18;316(5827):1039-43 - PubMed
  45. Arch Pathol Lab Med. 2008 Feb;132(2):248-60 - PubMed
  46. Nat Genet. 2012 Jul 01;44(8):852-60 - PubMed
  47. N Engl J Med. 2008 Jul 24;359(4):366-77 - PubMed
  48. J Thorac Oncol. 2014 Jul;9(7):947-56 - PubMed
  49. Lancet. 1997 Aug 16;350(9076):485-7 - PubMed
  50. Nat Med. 2016 Mar;22(3):262-9 - PubMed
  51. Lung Cancer. 2014 Nov;86(2):170-3 - PubMed
  52. Oncotarget. 2016 May 10;7(19):28748-60 - PubMed
  53. J Natl Cancer Inst. 2014 Aug 08;106(8):null - PubMed
  54. Sci Transl Med. 2011 Mar 23;3(75):75ra26 - PubMed
  55. N Engl J Med. 2016 Jan 7;374(1):54-61 - PubMed
  56. J Natl Cancer Inst. 1987 Sep;79(3):403-7 - PubMed
  57. J Clin Pathol. 2004 Jun;57(6):654-6 - PubMed
  58. Ann Oncol. 2014 Sep;25 Suppl 3:iii27-39 - PubMed
  59. Transl Lung Cancer Res. 2013 Jun;2(3):152-9 - PubMed
  60. J Clin Oncol. 2015 Oct 20;33(30):3488-515 - PubMed
  61. N Engl J Med. 2017 Feb 16;376(7):629-640 - PubMed
  62. Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5 - PubMed
  63. Nat Commun. 2015 Mar 11;6:6377 - PubMed
  64. Nat Med. 2014 May;20(5):548-54 - PubMed
  65. Ann Oncol. 2014 Feb;25(2):423-8 - PubMed
  66. Nat Med. 2015 Jun;21(6):560-2 - PubMed

Publication Types